Research & Development

The partnership is intended to bring together Dewpoint’s advanced oncolog y pipeline programmes with Evotec’s ability to derisk and accelerate preclinical development candidates to f irst-in-human clinical trials.

Under terms of the agreement, Evotec will facilitate the development of Dewpoint’s oncolog y assets using Evotec’s INDiGO platform to accelerate the path to clinical testing. This agreement is based on a risk-sharing arrangement followed by milestone and royalty pay ments to Evotec depending on the success of the overall programmes.

Dr Matthias Evers, chief business officer of Evotec, commented: “We are excited to enter this strategic development partnership with Dewpoint. Its innovative approach is based on a holistic understanding, which can significantly expand the target space across indications. By combining our complementar y expertise, Evotec’s development platform will serve as the capital-eff icient IND engine for this highly collaborative partnership. We look forward to working closely together with their team to make Dewpoint’s groundbreaking innovations available to patients.”

Ameet Nathwani MD, CEO at Dewpoint, added: “Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic. Evotec’s integrated state-of-the-art operational technologies have been proven to deliver high quality INDs across the industry. A strategic relationship of this nature significantly enhances our development capabilities, which can be transformative for a company at our stage of development, and we are delighted to have been able to forge this partnership with a leader like Evotec.”